Zobrazeno 1 - 10
of 176
pro vyhledávání: '"CGRP monoclonal antibodies"'
Autor:
Paolo Manganotti, Manuela Deodato, Laura D’Acunto, Francesco Biaduzzini, Gabriele Garascia, Antonio Granato
Publikováno v:
Neurology International, Vol 16, Iss 4, Pp 673-688 (2024)
Background: the aim of this study was to investigate the neurophysiological effect of anti-CGRP monoclonal antibodies on central and peripheral levels in migraine patients. Methods: An observational cohort study in patients with migraine was performe
Externí odkaz:
https://doaj.org/article/3a60b960a8fc4ac286338d33ffafc661
Autor:
Reem Suliman, Vanessa Santos, Ibrahim Al Qaisi, Batool Aldaher, Ahmed Al Fardan, Hajir Al Barrawy, Yazan Bader, Jonna Lyn Supena, Kathrina Alejandro, Taoufik Alsaadi
Publikováno v:
Neurology International, Vol 16, Iss 1, Pp 274-288 (2024)
Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) have shown promising effectiveness in migraine management compared to other preventative treatment options. Many questions remain regarding switching between antibody classes as a trea
Externí odkaz:
https://doaj.org/article/66f72f480afe4f638d79634380576608
Autor:
Christian Lampl, Antoinette MaassenVanDenBrink, Christina I. Deligianni, Raquel Gil-Gouveia, Tanvir Jassal, Margarita Sanchez-del-Rio, Uwe Reuter, Derya Uluduz, Jan Versijpt, Dena Zeraatkar, Simona Sacco
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-14 (2023)
Abstract Objective While there are several trials that support the efficacy of various drugs for migraine prophylaxis against placebo, there is limited evidence addressing the comparative safety and efficacy of these drugs. We conducted a systematic
Externí odkaz:
https://doaj.org/article/9944eb93d4ea4159a4778116aae42047
Autor:
M. T. Corasaniti, G. W. Lawrence, G. Bagetta, R. Iannacchero, A. Tarsitano, A. Monteleone, M. Pagliaro, P. Tonin, G. Sandrini, P. Nicotera, D. Scuteri
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Chronic migraine is a disabling neurovascular disorder that ranks amongst the top causes of years lived with disability worldwide. The duration and the frequency of migraine affect cognitive and affective domains, inducing worsening of memory, execut
Externí odkaz:
https://doaj.org/article/a44ca9b155fe43549fa815e38f443a1d
Publikováno v:
Neurologijos seminarai, Vol 26, Iss 3 (93) (2023)
Headache is one of the most common neurological symptoms associated with coronavirus disease 19 (COVID-19), which can mimic primary headache phenotypes. COVID-19 and quarantine have affected both the course of primary headache and patient care strate
Externí odkaz:
https://doaj.org/article/36f81bf345944b1fbaad6f825c0af68b
Autor:
Sait Ashina, Agustin Melo-Carrillo, Ajayi Toluwanimi, Nicolas Bolo, Edina Szabo, David Borsook, Rami Burstein
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-23 (2023)
Abstract Background The goal of this observational, open-label, cohort study was to determine whether prophylactic migraine treatment with galcanezumab, a peripherally acting drug, alters the incidence of premonitory symptoms, and/or occurrence of he
Externí odkaz:
https://doaj.org/article/e21a5934e17741fbae5dbf8298779d53
Autor:
Saval Khanal, Martin Underwood, Seyran Naghdi, Anna Brown, Callum Duncan, Manjit Matharu, Hema Mistry
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-27 (2022)
Abstract Background and aims Chronic migraine is a common neurovascular brain disorder with substantial economic costs. We performed a systematic review to identify economic evaluations of pharmacological treatments for adults with chronic migraine.
Externí odkaz:
https://doaj.org/article/9347b2b379314e4f89746c206cd3bc43
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
ObjectiveTo report the efficacy of different anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) on headache frequency, intensity, and duration.BackgroundBlockade of CGRP receptors or neuropeptide with anti-CGRP mAbs have been su
Externí odkaz:
https://doaj.org/article/036c0c66296143a289d037996e512658
Autor:
Giulia Ceccardi, Francesca Schiano di Cola, Salvatore Caratozzolo, Michele Di Pasquale, Marco Bolchini, Alessandro Padovani, Renata Rao
Publikováno v:
Toxins, Vol 15, Iss 12, p 677 (2023)
The aim of the present study was to evaluate whether previous preventive treatment with onabotulinumtoxin-A might influence subsequent clinical response following a switch to anti-CGRP monoclonal antibodies (mAbs). The present retrospective study was
Externí odkaz:
https://doaj.org/article/e2820a4d909e44c08df7d1432b31634a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.